Advice
Following a full submission
Lanthanum carbonate (Fosrenol) is accepted for restricted use within NHS Scotland as a phosphate-binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis.
Lanthanum carbonate is as effective as calcium carbonate in reducing phosphate to target levels. It is restricted to use as a second-line agent in patients where a non-aluminium, noncalcium phosphate binder is required.
Download detailed advice81KB (PDF)
Medicine details
- Medicine name:
- lanthanum carbonate 500, 750, 1000mg chewable tablets (Fosrenol)
- SMC ID:
- 286/06
- Indication:
- Control of hyperphosphataemia in chronic renal failure patients
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 07 May 2007
Additional notes